ACT Biotech is a privately-held biopharmaceutical company focused on the development and commercialization of targeted, orally available cancer drugs.
The Company’s four programs each target a different family of receptor tyrosine kinases. Three of the programs target well validated anti-cancer receptors and have been rationally designed to overcome the drawbacks of first generation molecules. The fourth program targets a unique set of receptors to provide a combination of anti-cancer modalities not available in any other anti-cancer agent.
The company was founded in 2008 by Wolf Busse and Ali Fattaey, experienced executives with decades of combined experience in oncology drug research and development in both big pharma and biotech companies. The products upon which the company was founded are highly validated in multiple pre-clinical and clinical studies. They were originally developed at Bayer Pharmaceuticals and were licensed by ACT Biotech in 2008 following Bayer’s merger with Schering AG.
ACT Biotech's venture investor is NGN Capital of New York, Connecticut and Heidelberg, Germany. The company is located in San Francisco, California.